Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Michela Rinaldini"'
Autor:
Francesco Boccardo, Domenico Amoroso, F. Genta, Alberto Ballestrero, Franco Patrone, Paola Stura, Mario Mesiti, Piero Sismondi, Fulvio Brema, Alessandra Rubagotti, Fabio Ferrando, Michela Rinaldini
Objectives: The purpose of this study was to evaluate the clinical efficacy and tolerability of high-dose (HD) chemotherapy with growth factor support in primary breast cancer with extensive nodal involvement. Patients and Methods: Fifty-three patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b2d01060a203737e6c9e23e52d9f787
http://hdl.handle.net/2318/10140
http://hdl.handle.net/2318/10140
Autor:
Renato Algeri, F. Pepi, Roberto Righi, Enrico Tucci, Michela Rinaldini, Paolo Ghezzi, Antonio Andrei, Carmine Santomaggio, Antonio Bellezza
Publikováno v:
American journal of clinical oncology. 21(1)
The aim of this study was to identify a chemotherapy combination that would be active and well tolerated for palliative treatment of advanced non-small-cell lung cancer (NSCLC). From February 1992 to December 1994, a total of 77 patients affected by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54814bdf5a113e2d3acadc307a7fe993
https://pubmed.ncbi.nlm.nih.gov/9499262
https://pubmed.ncbi.nlm.nih.gov/9499262
Autor:
V. Distante, R. Franchi, Matteo Puntoni, Mario Mesiti, Francesco Boccardo, Alessandra Rubagotti, M. Porpiglia, Pamela Guglielmini, Michela Rinaldini, G. Paladini
Publikováno v:
Journal of Clinical Oncology. 23:526-526
526 Background: We have previously shown that switching to ANA after 2–3 years of TAM is well tolerated and significantly improves event-free (EFS) and progression-free survival (PFS) of postmenopa...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16a7bb1534ee188e8f86516519d7f305
https://doi.org/10.1200/jco.2005.23.16_suppl.526
https://doi.org/10.1200/jco.2005.23.16_suppl.526